Is there an ideal antiarrhythmic drug? A review — with particular reference to class I antiarrhythmic agents

Muhiddin, Khulood A.; Turner, Paul

doi:10.1136/pgmj.61.718.665

Cited by 5 publications

(1 citation statement)

References 87 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Amiodarone, a broad-spectrum antiarrhythmic drug, has limited long-term suitability in patients with heart failure (HF) due to its extracardiac toxicity ( 2 ). Ideal antiarrhythmic drugs can prevent serious arrhythmias, effectively control the ectopic rhythm, restore or maintain sinus rhythm, and have no toxic effects on hemodynamics and vital organs ( 3 ). The search continues for better antiarrhythmic drugs.…”

Section: Introductionmentioning

confidence: 99%

Exploration of Mechanisms of Sacubitril/Valsartan in the Treatment of Cardiac Arrhythmias Using a Network Pharmacology Approach

Zhou

Rui

Tang

et al. 2022

Front. Cardiovasc. Med.

View full text Add to dashboard Cite

Significant reductions in the incidence of cardiac arrhythmia (CA) and sudden cardiac death (SCD), along with amelioration of heart failure, have been reported for treatment with Sacubitril/valsartan (SV). However, its anti-arrhythmic mechanism remains unclear. The current study aims to explore the anti-arrhythmic molecular mechanism of SV. The direct protein targets (DPT) of SV were extracted from DrugBank. The protein-protein interaction (PPI) network of SV DPTs was constructed using STRING, and the indirect protein targets (IPTs) were also identified. A search for arrhythmia-related genes was conducted using GeneCards and the Comparative Toxicogenomics Database (CTD). The DTPs, ITPs, and arrhythmia-related genes from the two datasets were combined in a Venn diagram, and the overlapping genes were identified as core target genes. The Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analyses identified the top 20 biological processes and signaling pathways related to disease and the therapeutic effects of SV. The renin-angiotensin system, adrenergic signaling in cardiomyocytes, and gap junction pathways are strongly implicated in the effects of SV on CA. In conclusion, our bioinformatics analyses provided evidence pertaining to the possible antiarrhythmic mechanisms of SV and may contribute to the development of novel drugs for CA.

show abstract

Section: Introductionmentioning

confidence: 99%

Exploration of Mechanisms of Sacubitril/Valsartan in the Treatment of Cardiac Arrhythmias Using a Network Pharmacology Approach

Zhou

Rui

Tang

et al. 2022

Front. Cardiovasc. Med.

View full text Add to dashboard Cite

show abstract

Effect of SC‐40230, a new class I antiarrhythmic agent, on canine ventricular tachycardias

Garthwaite

Hatley

Frederick

et al. 1989

Drug Development Research

View full text Add to dashboard Cite

Garthwaite, S., F. Hatley, L. Frederick, J. Ruby, and C. Cook: Effect of SC-40230, A new class I antiarrhythmic agent, on canine ventricular tachycardias. Drug Dev. Res. 17:119-133, 1989. SC-40230, a-[2-[acetyl( 1 -methylethyl)amino]ethyl]-tr-(2-chlorophenyl)-l -piperidinebutanamide, a new class I antiarrhythmic agent, was tested for efficacy against coronary ligation-induced arrhythmias and ouabain toxicity arrhythmias in dogs. Doses of 9 mg/kg i.v. and 15, 25, and 35 mgikg p.0. significantly reduced ectopic rate in conscious dogs that had undergone ligation of the left anterior descending coronary artery 24 hr prior to testing. Plasma concentrations of SC-40230 ranging from 3 to 9 pg/ml corresponded with ectopic rate reductions of 10-82% in the coronary ligation model. was well tolerated at all doses tested in the conscious dogs. A 5 mgikg i.v. dose of SC-40230 converted ouabain-induced ventricular tachycardias to normal sinus rhythm in anesthetized dogs. The antiarrhythmic effect of SC-40230 in the ouabain toxicity model was reversed by large ( 5 240 U) doses of insulin. The experiments described in this study demonstrated that SC-40230 is a well-tolerated new class I antiarrhythmic agent with intravenous and oral effectiveness against ventricular arrhythmias.

show abstract

Antiarrhythmic drugs

Hamer¹

1987

Drugs for Heart Disease

View full text Add to dashboard Cite

Is there an ideal antiarrhythmic drug? A review — with particular reference to class I antiarrhythmic agents

Cited by 5 publications

References 87 publications

Exploration of Mechanisms of Sacubitril/Valsartan in the Treatment of Cardiac Arrhythmias Using a Network Pharmacology Approach

Exploration of Mechanisms of Sacubitril/Valsartan in the Treatment of Cardiac Arrhythmias Using a Network Pharmacology Approach

Effect of SC‐40230, a new class I antiarrhythmic agent, on canine ventricular tachycardias

Antiarrhythmic drugs

Contact Info

Product

Resources

About